GlassScriptPhysician profile
Anum Abbas
NPI 1548048671
$778.46
in general payments reported to CMS, 2019-2025
13 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $224 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $188.90 | 2024-2025 | Eliquis, Camzyos |
| Actelion Pharmaceuticals US, INC. | $117.77 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $79.63 | 2025 | |
| Philips North America LLC | $69.46 | 2024 | (Cm9) Amb Mon & Diag Und |
| Pfizer INC. | $62.85 | 2024-2025 | |
| Boston Scientific Corporation | $54.47 | 2025 | Watchman Flx |
| Amgen INC. | $50.15 | 2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.37 | 2024 | Jardiance |
| Genzyme Corporation | $31.11 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $27.10 | 2024 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $25.70 | 2025 | Amvuttra |
| Vivaquant INC, Dba Rhythm Express | $16.05 | 2025 | Rhythm Express |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.90 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anum Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.